| Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
|
(Celgene)
|
03-Jun-2008 |
| Methylgene Reports Clinical Data From a Phase II Study Evaluating MGCD0103 in Relapsed or Refractory Non-Hodgkin Lymphomas at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
|
(MethylGene)
|
03-Jun-2008 |
| Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
|
(Celgene)
|
02-Jun-2008 |
| Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
|
(Celgene)
|
02-Jun-2008 |
| New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting
|
(GPC Biotech)
|
02-Jun-2008 |
| MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
|
(MethylGene)
|
02-Jun-2008 |
| Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
|
(GPC Biotech)
|
02-Jun-2008 |
| Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
|
(Celgene)
|
01-Jun-2008 |
| Updated REVLIMID(R) Results Presented In Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO
|
(Celgene)
|
01-Jun-2008 |
| Clinical Data for MethylGene's MGCD0103 to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting
|
(MethylGene)
|
16-May-2008 |
| Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells
|
(Celgene)
|
02-May-2008 |
| Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
|
(Celgene)
|
21-Apr-2008 |
| MethylGene Provides Update on Its MGCD0103 Hdac Inhibitor Collaboration With Celgene
|
(MethylGene)
|
15-Apr-2008 |
| MethylGene Presents Clinical Biomarker Data for MGCD0103 and Preclinical Efficacy Data in Combination With Taxanes at AACR Annual Meeting
|
(MethylGene)
|
14-Apr-2008 |
| Amrubicinis Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer
|
(Celgene)
|
11-Apr-2008 |
| Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
|
(Celgene)
|
07-Apr-2008 |
| Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
|
(Celgene)
|
25-Mar-2008 |
| Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS)
|
(Seattle Genetics)
|
20-Mar-2008 |
| Pharmacopeia Collaboration with Celgene Corporation Advances Compound Into Phase 1 Clinical Development
|
(Pharmacopeia)
|
05-Mar-2008 |
| Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
|
(Celgene)
|
19-Feb-2008 |
| Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
|
(Pharmion)
|
14-Feb-2008 |
| MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
|
(MethylGene)
|
14-Feb-2008 |
| Millennium must work hard for Velcade advantage
|
(Millennium Pharmaceuticals)
|
12-Feb-2008 |
| Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
|
(Pharmion)
|
11-Feb-2008 |
| MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous
|
(MethylGene)
|
11-Feb-2008 |
| Pharmion shareholder raises the stakes
|
(Pharmion)
|
08-Feb-2008 |
| EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
|
(Pharmion)
|
07-Feb-2008 |
| Clinical Data Reported on Celgene Compound Apremilast (CC-10004) Evaluating Efficacy, Safety and Quality of Life Improvement for Psoriasis Patients
|
(Celgene)
|
04-Feb-2008 |
| MethylGene Reports MGCD0103 Clinical Data at the 2008 Gastrointestinal Cancers Symposium
|
(MethylGene)
|
28-Jan-2008 |
| Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
|
(Celgene)
|
24-Jan-2008 |
| Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
|
(Pharmion)
|
24-Jan-2008 |
| Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
|
(Pharmion)
|
14-Jan-2008 |
| Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
|
(Pharmion)
|
09-Jan-2008 |
| MethylGene and Pharmion Start Phase II Combination Clinical Trial With MGCD0103 and Vidaza® in Patients With Relapsed Or Refractory Hodgkin Lymphoma Or Non-hodgkin Lymphoma
|
(MethylGene)
|
09-Jan-2008 |
| MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-Day Schedule
|
(Pharmion)
|
11-Dec-2007 |
| REVLIMID(R) (Lenalidomide) in Combination with Rituximab Demonstrates 70% Overall Response Rate in Hard to Treat Relapsed/Refractory Mantle Cell Lymphoma
|
(Celgene)
|
10-Dec-2007 |
| Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
|
(Pharmion)
|
10-Dec-2007 |
| MethylGene and Pharmion Present Favorable Clinical Data from Combination MGCD0103/Vidaza® Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at the 49th American Society of Hematology (ASH) Meeting
|
(MethylGene)
|
10-Dec-2007 |
| Two Studies Demonstrate REVLIMID(R) (lenalidomide) Activity in Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
|
(Celgene)
|
10-Dec-2007 |
| SWOG Phase III Trial Reports REVLIMID(R) (lenalidomide) Plus Dexamethasone Achieves Superior Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients
|
(Celgene)
|
09-Dec-2007 |
| Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
|
(Pharmion)
|
09-Dec-2007 |
| Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
|
(Pharmion)
|
09-Dec-2007 |
| Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients with Myelodysplastic Syndromes (MDS)
|
(Pharmion)
|
09-Dec-2007 |
| MethylGene and Pharmion Report Favorable Results for Phase II MGCD0103 Single-agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
|
(MethylGene)
|
09-Dec-2007 |
| REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
|
(Celgene)
|
09-Dec-2007 |
| Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
|
(Pharmion)
|
06-Dec-2007 |
| Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
|
(Celgene)
|
30-Nov-2007 |
| Updated REVLIMID(R) (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in The New England Journal of Medicine
|
(Celgene)
|
21-Nov-2007 |
| Two Major Phase III Studies Report Oral REVLIMID(R) (Lenalidomide) Plus Dexamethasone Shows Increased Overall Survival Advantage to Dexamethasone Plus Placebo in Previously Treated Multiple Myeloma Patients in The New England Journal of Medicine
|
(Celgene)
|
21-Nov-2007 |
| Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
|
(Celgene)
|
12-Nov-2007 |
| Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
|
(Pharmion)
|
09-Nov-2007 |
| GPC, Pharmion's phase III failure could raise eyebrows at Poniard
|
(GPC Biotech)
|
31-Oct-2007 |
| Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
|
(Pharmion)
|
30-Oct-2007 |
| GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
|
(GPC Biotech)
|
30-Oct-2007 |
| Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
|
(Pharmion)
|
24-Oct-2007 |
| MethylGene and Pharmion Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
|
(MethylGene)
|
24-Oct-2007 |
| Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
|
(Pharmion)
|
17-Oct-2007 |
| Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
|
(Pharmion)
|
10-Oct-2007 |
| MethylGene and Pharmion Initiate Phase I Combination Clinical Trial With MGCD0103 and Taxotere® in Patients With Solid Tumors
|
(MethylGene)
|
10-Oct-2007 |
| Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
|
(Pharmion)
|
24-Sep-2007 |
| MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
|
(MethylGene)
|
24-Sep-2007 |
| Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
|
(Celgene)
|
17-Sep-2007 |
| Oral Cancer Drug REVLIMID® Receives Swissmedic Approval in Switzerland For Treatment of Multiple Myeloma
|
(Celgene)
|
04-Sep-2007 |
| Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
|
(Pharmion)
|
29-Aug-2007 |
| Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
|
(Pharmion)
|
21-Aug-2007 |
| MethylGene and Pharmion Announce U.S.Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
|
(MethylGene)
|
21-Aug-2007 |
| Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
|
(Pharmion)
|
02-Aug-2007 |
| Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines Agency
|
(Spectrum Pharmaceuticals)
|
27-Jul-2007 |
| MethylGene Initiates Single-agent Phase II Clinical Trial With Its HDAC Inhibitor, MGCD0103, in Patients With Refractory Chronic Lymphocytic Leukemia
|
(MethylGene)
|
12-Jul-2007 |
| GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin
|
(GPC Biotech)
|
26-Jun-2007 |
| Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination with Prednisone for the Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
|
(Pharmion)
|
26-Jun-2007 |
| Marketing Authorization Application Filed for Satraplatin With the European Medicines Agency
|
(Spectrum Pharmaceuticals)
|
26-Jun-2007 |
| REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
|
(Celgene)
|
19-Jun-2007 |
